Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARQT NASDAQ:INVA NASDAQ:OCUL NASDAQ:PHAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$17.38$15.79$8.03▼$18.15$2.08B1.931.56 million shs1.06 million shsINVAInnoviva$19.04-0.8%$19.65$16.67▼$22.00$1.21B0.47700,739 shs1.27 million shsOCULOcular Therapeutix$12.20+0.8%$12.24$5.78▼$13.85$2.11B1.52.30 million shs2.18 million shsPHATPhathom Pharmaceuticals$11.74+4.7%$10.42$2.21▼$19.50$795.28M0.441.08 million shs565,713 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics0.00%+0.52%+8.76%+20.69%+71.23%INVAInnoviva0.00%-0.93%-4.81%-7.83%-0.88%OCULOcular Therapeutix0.00%-5.54%-1.63%+44.56%+34.74%PHATPhathom Pharmaceuticals0.00%-5.32%-5.88%+18.37%-39.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARQTArcutis Biotherapeutics$17.38$15.79$8.03▼$18.15$2.08B1.931.56 million shs1.06 million shsINVAInnoviva$19.04-0.8%$19.65$16.67▼$22.00$1.21B0.47700,739 shs1.27 million shsOCULOcular Therapeutix$12.20+0.8%$12.24$5.78▼$13.85$2.11B1.52.30 million shs2.18 million shsPHATPhathom Pharmaceuticals$11.74+4.7%$10.42$2.21▼$19.50$795.28M0.441.08 million shs565,713 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARQTArcutis Biotherapeutics0.00%+0.52%+8.76%+20.69%+71.23%INVAInnoviva0.00%-0.93%-4.81%-7.83%-0.88%OCULOcular Therapeutix0.00%-5.54%-1.63%+44.56%+34.74%PHATPhathom Pharmaceuticals0.00%-5.32%-5.88%+18.37%-39.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARQTArcutis Biotherapeutics 2.86Moderate Buy$19.8013.92% UpsideINVAInnoviva 3.00Buy$42.75124.53% UpsideOCULOcular Therapeutix 3.00Buy$17.8346.17% UpsidePHATPhathom Pharmaceuticals 3.00Buy$17.5049.06% UpsideCurrent Analyst Ratings BreakdownLatest INVA, ARQT, OCUL, and PHAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/15/2025OCULOcular TherapeutixChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$21.008/11/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$40.00 ➝ $45.008/11/2025INVAInnovivaOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$45.008/7/2025ARQTArcutis BiotherapeuticsCowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy8/7/2025ARQTArcutis BiotherapeuticsNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$20.00 ➝ $22.008/6/2025OCULOcular TherapeutixScotiabankSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetSector Outperform$22.00 ➝ $20.008/5/2025OCULOcular TherapeutixNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$14.00 ➝ $15.007/25/2025ARQTArcutis BiotherapeuticsThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$18.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.007/14/2025INVAInnovivaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$40.007/11/2025INVAInnovivaCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$26.00(Data available from 9/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARQTArcutis Biotherapeutics$196.54M10.60N/AN/A$1.35 per share12.87INVAInnoviva$358.71M3.35$3.40 per share5.60$11.03 per share1.73OCULOcular Therapeutix$63.72M33.31N/AN/A$2.01 per share6.07PHATPhathom Pharmaceuticals$55.25M15.07N/AN/A($3.71) per share-3.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARQTArcutis Biotherapeutics-$140.04M-$0.75N/AN/AN/A-35.40%-62.62%-25.16%11/5/2025 (Estimated)INVAInnoviva$23.39M$0.3161.4212.28N/A10.44%18.67%9.92%11/5/2025 (Estimated)OCULOcular Therapeutix-$193.51M-$1.28N/AN/AN/A-382.51%-71.92%-49.36%11/13/2025 (Estimated)PHATPhathom Pharmaceuticals-$334.33M-$4.73N/AN/AN/A-289.51%N/A-90.40%11/6/2025 (Estimated)Latest INVA, ARQT, OCUL, and PHAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ARQTArcutis Biotherapeutics-$0.18-$0.13+$0.05-$0.13$72.70 million$81.50 million8/6/2025Q2 2025INVAInnoviva$0.57$0.77+$0.20$0.77$87.10 million$100.28 million8/5/2025Q2 2025OCULOcular Therapeutix-$0.35-$0.39-$0.04-$0.39$13.12 million$13.46 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARQTArcutis BiotherapeuticsN/AN/AN/AN/AN/AINVAInnovivaN/AN/AN/AN/AN/AOCULOcular TherapeutixN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARQTArcutis Biotherapeutics0.773.203.04INVAInnoviva0.362.642.44OCULOcular Therapeutix0.2310.1010.02PHATPhathom PharmaceuticalsN/A2.382.35Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARQTArcutis BiotherapeuticsN/AINVAInnoviva99.12%OCULOcular Therapeutix59.21%PHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipARQTArcutis Biotherapeutics9.40%INVAInnoviva2.25%OCULOcular Therapeutix2.30%PHATPhathom Pharmaceuticals24.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARQTArcutis Biotherapeutics150119.90 million108.63 millionOptionableINVAInnoviva10063.02 million61.60 millionOptionableOCULOcular Therapeutix230173.99 million169.99 millionOptionablePHATPhathom Pharmaceuticals11070.94 million53.85 millionOptionableINVA, ARQT, OCUL, and PHAT HeadlinesRecent News About These CompaniesGoldman Sachs Group Inc. Cuts Stake in Phathom Pharmaceuticals, Inc. $PHATSeptember 22 at 3:14 AM | marketbeat.comPhathom Pharmaceuticals (PHAT) Upgraded to Buy: Here's WhySeptember 18, 2025 | zacks.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 4.1% - Here's What HappenedSeptember 16, 2025 | marketbeat.comFDA targets Lilly, Novartis, BMS and more in deluge of marketing lettersSeptember 16, 2025 | fiercepharma.comFCheck out 15 DTC pharma ads that got flagged by FDASeptember 16, 2025 | mmm-online.comMFDA Letters Flag Oprah Video, Morgan Freeman Ad in CrackdownSeptember 16, 2025 | msn.comWoodline Partners LP Decreases Stake in Phathom Pharmaceuticals, Inc. $PHATSeptember 15, 2025 | marketbeat.com596,108 Shares in Phathom Pharmaceuticals, Inc. $PHAT Bought by Jacobs Levy Equity Management Inc.September 12, 2025 | marketbeat.comWall Street Analysts See a 66.13% Upside in Phathom Pharmaceuticals (PHAT): Can the Stock Really Move This High?September 8, 2025 | zacks.comPhathom Pharmaceuticals: The IP Question Is Answered, But Can Management Deliver (Rating Upgrade)September 8, 2025 | seekingalpha.comNuveen LLC Makes New $637,000 Investment in Phathom Pharmaceuticals, Inc. $PHATSeptember 6, 2025 | marketbeat.com683 Capital Management LLC Grows Holdings in Phathom Pharmaceuticals, Inc. $PHATSeptember 4, 2025 | marketbeat.comRussell Investments Group Ltd. Purchases Shares of 41,799 Phathom Pharmaceuticals, Inc. $PHATSeptember 3, 2025 | marketbeat.comPropel Bio Management LLC Has $7.12 Million Stock Holdings in Phathom Pharmaceuticals, Inc. $PHATSeptember 2, 2025 | marketbeat.comWellington Management Group LLP Raises Stock Holdings in Phathom Pharmaceuticals, Inc. $PHATSeptember 2, 2025 | marketbeat.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Receives Consensus Recommendation of "Buy" from AnalystsSeptember 2, 2025 | marketbeat.comPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesAugust 25, 2025 | globenewswire.comWall Street Analysts Think Phathom Pharmaceuticals (PHAT) Could Surge 87.21%: Read This Before Placing a BetAugust 22, 2025 | zacks.comPhathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder’s Ownership Following Administrative Change to 13D FilingAugust 20, 2025 | taiwannews.com.twTPhathom Pharmaceuticals Clarifies That There Is No Reduction in Lead Shareholder's Ownership Following Administrative Change to 13D FilingAugust 20, 2025 | globenewswire.comPhathom Pharmaceuticals (PHAT) Gets a Buy from H.C. WainwrightAugust 14, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeINVA, ARQT, OCUL, and PHAT Company DescriptionsArcutis Biotherapeutics NASDAQ:ARQT$17.38 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$17.40 +0.02 (+0.09%) As of 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing ARQ-154, a topical ZORYVE for the treatment of scalp and body psoriasis and seborrheic dermatitis; ARQ-252, a selective topical janus kinase type 1 inhibitor for hand eczema and vitiligo; ARQ-255, a topical JAK1 inhibitor for alopecia areata; and ARQ-234, a CD200R fusion protein for the treatment of moderate-to-severe atopic dermatitis. The company was formerly known as Arcutis, Inc. and changed its name to Arcutis Biotherapeutics, Inc. in October 2019. Arcutis Biotherapeutics, Inc. was incorporated in 2016 and is headquartered in Westlake Village, California.Innoviva NASDAQ:INVA$19.04 -0.15 (-0.78%) Closing price 04:00 PM EasternExtended Trading$18.91 -0.13 (-0.68%) As of 07:45 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Ocular Therapeutix NASDAQ:OCUL$12.20 +0.10 (+0.83%) Closing price 04:00 PM EasternExtended Trading$12.12 -0.08 (-0.70%) As of 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is developing AXPAXLI, an axitinib intravitreal implant that is in phase 3 trials for the treatment of wet age-related macular degeneration and other retinal diseases; PAXTRAVA, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease. In addition, the company offers modulator for intermediate and late dry age-related macular degeneration; and gene delivery for inherited retinal degenerations and protein biofactory indications. The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.Phathom Pharmaceuticals NASDAQ:PHAT$11.74 +0.53 (+4.73%) Closing price 04:00 PM EasternExtended Trading$11.64 -0.10 (-0.81%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 High-Yields at 52-Week Lows: Buy, Sell, or Hold Advance Auto Parts is A Great Risk/Reward Play If EPS Delivers 3 Small Caps That Insiders Are Buying Banks Boost Gold Forecasts: One Sees +30% Bull-Case Potential These 3 Stocks Boosting Buybacks Have Rallying Potential GameStop Partying Like It’s 2021: What’s Behind Its 2025 Rebound? Hims & Hers Stock Pushes to Highs on Healthcare Rate Cut Frenzy Why Robinhood Stock Is Soaring—and What Comes Next Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
